What Is EU FMD (Falsified Medicines Directive)?
EU FMD (Falsified Medicines Directive) is a European Union regulation designed to prevent falsified, counterfeit or illegally altered medicines from entering the legal supply chain. Implemented in 2019, FMD mandates unique identification, tamper-evident packaging and end-to-end verification for all prescription medicines sold within the EU.
How EU FMD Works in Practice
The system relies on a central verification infrastructure known as the EMVS (European Medicines Verification System), enabling real-time authentication at pharmacies and dispensing points. The European Medicines Agency's falsified medicines overview sets out the legal framework; it is one of the strongest anti-counterfeit frameworks globally.
- The manufacturer serialises packs and uploads data to the EMVS
- Wholesalers verify product identity during receipt and distribution
- At the pharmacy, the pack is scanned through national verification systems
- If the serial is valid, the system approves dispensing
- If the pack is suspicious (stolen, duplicated, expired), it is quarantined
This ensures only genuine medicines reach patients across manufacturers, CMOs, distributors, and hospital and retail pharmacies.
Example: EU FMD at a Pharmacy Counter
A pharmacist scans a serialised box of antibiotics. The EMVS checks the serial number, batch and expiry, and the verification response returns "active and authentic". The pharmacist dispenses the medicine and the system decommissions the pack so it cannot re-enter the supply chain. If the status had been "unknown" or "already dispensed", the pack would be isolated immediately.
Key Requirements Under EU FMD
Objectives of EU FMD
The directive exists to protect patients and the pharmaceutical supply chain:
- Protects patients from counterfeit or unsafe medicines
- Ensures authenticity at the point of dispensing
- Improves supply chain transparency
- Enforces standardised safety features across all EU member states
- Strengthens trust in Europe's pharmaceutical ecosystem
How Acviss Supports EU FMD Alignment
Acviss helps pharmaceutical brands strengthen and complement FMD requirements through serialisation and secure QR code generation, tamper-evident and non-cloneable label technologies, and Digital Twin traceability linked to FMD data.
Authentication events, anomaly detection and audit-ready logs through Origin add extra layers of anti-counterfeiting protection on top of baseline FMD compliance.
Go Beyond FMD Compliance with Acviss Serialisation
Origin and Certify add non-cloneable identity, real-time verification and audit-ready traceability on top of your FMD workflows. Built for pharmaceutical brands and manufacturers.
Book a Free DemoFrequently Asked Questions
An EU regulation, in force since 2019, that prevents falsified medicines from entering the legal supply chain. It mandates a unique identifier on every prescription medicine pack, tamper-evident packaging and end-to-end verification through the EMVS.
Five core requirements: a unique identifier (GTIN, serial number, batch and expiry) on every pack, a tamper-evident seal, upload of serialised data to the EMVS, verification by scan at the pharmacy, and decommissioning of each pack once dispensed.
The manufacturer serialises packs and uploads data to the EMVS. Wholesalers verify identity during receipt and distribution. At the pharmacy the pack is scanned through the national verification system: a valid serial approves dispensing, while a suspicious pack is quarantined immediately.
All prescription medicine manufacturers, contract manufacturing organisations (CMOs), pharmaceutical distributors, and hospital and retail pharmacies operating in the EU. Non-prescription medicines may be included based on national rules.
Marking a pack's unique identifier as inactive in the EMVS once it is dispensed, exported or destroyed. Decommissioning prevents the same serial number from being reused on a falsified pack or a diverted product re-entering the supply chain.
